Scopus Publication Detail
The publication detail shows the title, authors (with indicators showing other profiled authors), information on the publishing organization, abstract and a link to the article in Scopus. This abstract is what is used to create the fingerprint of the publication.
Abigail B. Shoben; Gregory Levin; Ian H. De Boer; Catherine Yeung; Suzanne Watnick; Ernie Ayers; Bryan Kestenbaum (Profiled Author: Suzanne Watnick)
American Journal of Kidney Diseases. 2012;59(5):645-652.Abstract
Background: Oral calcitriol decreases parathyroid hormone (PTH) concentrations in patients who have chronic kidney disease (CKD); however, treatment response is highly variable. We evaluated whether patient characteristics affect the PTH response to oral calcitriol in nondialysis patients with CKD in a clinic-based setting. Study Design: Cohort study. Setting & Participants: This study included 379 new oral calcitriol users in the Veterans' Affairs Northwest Health Network. All had stages 3-4 CKD, hyperparathyroidism, and a serum PTH measurement before and 1-6 months after initiating oral calcitriol therapy. Predictors: Patient-level characteristics hypothesized to affect calcitriol response: race, body size, concurrent medications, and kidney function. Outcomes: Relative decrease in serum PTH concentration after starting oral calcitriol therapy. Measurements: Data were abstracted from the Veterans' Affairs Northwest Health Network (VISN 20) Data Warehouse, which includes electronic pharmacy and laboratory records. Results: Mean estimated glomerular filtration rate was 30 mL/min/1.73 m 2 and mean initial PTH concentration was 199 pg/mL. Regular- (0.25 μg/d) and low-dose (<0.25 μg/d) oral calcitriol were associated with on average 23% and 13% relative decreases in serum PTH concentrations, respectively. After adjustment for calcitriol dosage, initial PTH concentration, and time to follow-up measurement, African American race was associated with a blunted calcitriol response (geometric mean final PTH value, 26% higher; 95% CI, 8%-47%). Serum albumin concentration <3.5 g/dL also was associated with a diminished calcitriol response (geometric mean final PTH, 19% higher; 95% CI, 6%-35%). Although numbers were small, concurrent use of benzodiazepines and nonactivated vitamin D supplements was associated with a significantly greater PTH response. Limitations: Clinic-based study is limited by the availability of PTH measurements after starting calcitriol therapy. Study of a predominantly older male population. Conclusions: In patients with stages 3-4 CKD, African American race and low serum albumin level are associated with a diminished PTH response to oral calcitriol. © 2012 National Kidney Foundation, Inc.
PMID: 22285224 PMCID: PMC3328668
This section shows information related to the publication - computed using the fingerprint of the publication - including related publications, related experts with fingerprints representing significant amounts of overlap between their fingerprint and this publication. The red dots indicate whether those experts or terms appear within the publication, thereby showing potential and actual connections.
Richard Marsell; Elin Grundberg; Tijana Krajisnik; Hans Mallmin; Magnus Karlsson; Dan Mellström; Eric Orwoll; Claes Ohlsson; Kenneth B. Jonsson; Östen Ljunggren; et al.European Journal of Endocrinology. 2008;158(1):125-129.
Eric S. Johnson; Jessica R. Weinstein; Micah L. Thorp; Robert W. Platt; Amanda F. Petrik; Xiuhai Yang; Sharon Anderson; David H. SmithPharmacoepidemiology and Drug Safety. 2010;19(3):266-272.
Christine Tompkins; Rhondalyn McLean; Alan Cheng; Jeffrey A. Brinker; Joseph E. Marine; Saman Nazarian; David D. Spragg; Sunil Sinha; Henry Halperin; Gordon F. Tomaselli; et al.Journal of Cardiovascular Electrophysiology. 2011;22(10):1099-1104.
Appears in this Document